Xolair
Blow for Novartis as ligelizumab can’t top Xolair in phase 3
Phil Taylor
chronic spontaneous urticaria, fenebrutinib, Immunology and inflammation, ligelizumab, Novartis, remibrutinib, Roche, Xolair
0 Comment
X
Blow for Novartis as ligelizumab can’t top Xolair in phase 3
https://pharmaphorum.com/news/blow-for-novartis-as-ligelizumab-cant-top-xolair-in-phase-3/
News/ News/ News/ Patients/ R&D
Ligelizumab could top Xolair in chronic hives, says Novartis
Phil Taylor
dermatology, hives, immunology, Novartis, Roche, Xolair
0 Comment
X
Ligelizumab could top Xolair in chronic hives, says Novartis
https://pharmaphorum.com/news/ligelizumab-could-top-xolair-in-chronic-hives-says-novartis/
X
Novartis takes Xolair follow-up into phase III hives trial
https://pharmaphorum.com/news/novartis-takes-xolair-follow-up-into-phase-iii-hives-trial/
Market Access/ News/ News/ Novartis/ Roche
Breakthrough designation for Roche/Novartis’ Xolair in food allergies
X
Breakthrough designation for Roche/Novartis’ Xolair in food allergies
https://pharmaphorum.com/news/breakthrough-designation-for-roche-novartis-xolair-in-food-allergies/